These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 38252289)

  • 21. Different Aspects of Classical Pathway Overactivation in Patients With C3 Glomerulopathy and Immune Complex-Mediated Membranoproliferative Glomerulonephritis.
    Michels MAHM; van de Kar NCAJ; van Kraaij SAW; Sarlea SA; Gracchi V; Engels FAPT; Dorresteijn EM; van der Deure J; Duineveld C; Wetzels JFM; van den Heuvel LPWJ; Volokhina EB
    Front Immunol; 2021; 12():715704. PubMed ID: 34456924
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anti-Factor H Antibody-Associated Atypical Hemolytic Uremic Syndrome: A Case Report.
    Abazi-Emini N; Sahpazova E; Putnik J; Tasic V
    Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2021 Oct; 42(2):109-115. PubMed ID: 34699711
    [No Abstract]   [Full Text] [Related]  

  • 23. Variants in complement genes are uncommon in patients with anti-factor H autoantibody-associated atypical hemolytic uremic syndrome.
    Khandelwal P; Joshi A; Mathur A; Puraswani M; Gurjar BS; Sinha A; Hari P; Faruq M; Bagga A
    Pediatr Nephrol; 2023 Aug; 38(8):2659-2668. PubMed ID: 36622444
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genetic abnormalities in biopsy-proven, adult-onset hemolytic uremic syndrome and C3 glomerulopathy.
    Haydock L; Garneau AP; Tremblay L; Yen HY; Gao H; Harrisson R; Isenring P
    J Mol Med (Berl); 2022 Feb; 100(2):269-284. PubMed ID: 34714369
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Atypical haemolytic uremic syndrome (aHUS) and membranoproliferative glomerulonephritis (MPGN), different diseases or a spectrum of complement-mediated glomerular diseases?
    Ankawi GA; Clark WF
    BMJ Case Rep; 2017 Aug; 2017():. PubMed ID: 28798244
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Overactivity of Alternative Pathway Convertases in Patients With Complement-Mediated Renal Diseases.
    Michels MAHM; van de Kar NCAJ; Okrój M; Blom AM; van Kraaij SAW; Volokhina EB; van den Heuvel LPWJ
    Front Immunol; 2018; 9():612. PubMed ID: 29670616
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Comparative characteristics of the complement system in patients with C3-glomerulopathy and atypical hemolytic uremic syndrome of chronic course who suffered an acute episode of thrombotic microangiopathy].
    Yurova VA; Kozlovskaya NL; Bobrova LA; Kozlov LV; Andina SS; Demyanova KA
    Ter Arkh; 2023 Aug; 95(6):475-480. PubMed ID: 38158966
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Propensity score-matched analysis of long-term outcomes for living kidney donation in alternative complement pathway diseases: a pilot study.
    Caliskan Y; Safak S; Oto OA; Velioglu A; Yelken B; Mirioglu S; Dirim AB; Yildiz A; Guller N; Yazici H; Ersoy A; Turkmen A; Lentine KL
    J Nephrol; 2023 May; 36(4):979-986. PubMed ID: 36808609
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Complement factor H, FHR-3 and FHR-1 variants associate in an extended haplotype conferring increased risk of atypical hemolytic uremic syndrome.
    Bernabéu-Herrero ME; Jiménez-Alcázar M; Anter J; Pinto S; Sánchez Chinchilla D; Garrido S; López-Trascasa M; Rodríguez de Córdoba S; Sánchez-Corral P
    Mol Immunol; 2015 Oct; 67(2 Pt B):276-86. PubMed ID: 26163426
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Factor H autoantibodies and deletion of Complement Factor H-Related protein-1 in rheumatic diseases in comparison to atypical hemolytic uremic syndrome.
    Foltyn Zadura A; Zipfel PF; Bokarewa MI; Sturfelt G; Jönsen A; Nilsson SC; Hillarp A; Saxne T; Trouw LA; Blom AM
    Arthritis Res Ther; 2012 Aug; 14(4):R185. PubMed ID: 22894814
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-factor H antibody and its role in atypical hemolytic uremic syndrome.
    Raina R; Mangat G; Hong G; Shah R; Nair N; Abboud B; Bagga S; Sethi SK
    Front Immunol; 2022; 13():931210. PubMed ID: 36091034
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differential contribution of C5aR and C5b-9 pathways to renal thrombic microangiopathy and macrovascular thrombosis in mice carrying an atypical hemolytic syndrome-related factor H mutation.
    Ueda Y; Miwa T; Ito D; Kim H; Sato S; Gullipalli D; Zhou L; Golla M; Song D; Dunaief JL; Palmer MB; Song WC
    Kidney Int; 2019 Jul; 96(1):67-79. PubMed ID: 30910380
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genetic and Protein Structural Evaluation of Atypical Hemolytic Uremic Syndrome and C3 Glomerulopathy.
    Perkins SJ
    Adv Chronic Kidney Dis; 2020 Mar; 27(2):120-127.e4. PubMed ID: 32553244
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mycoplasma pneumoniae Infection Associated with Anti-Factor H Autoantibodies in Atypical Hemolytic Uremic Syndrome.
    Valoti E; Piras R; Mele C; Alberti M; Liguori L; Breno M; Bertulli C; Bresin E; Donadelli R
    Nephron; 2022; 146(6):593-598. PubMed ID: 35405682
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of complement factor H-related (CFHR) proteins in plasma reveals novel genetic variations of CFHR1 associated with atypical hemolytic uremic syndrome.
    Abarrategui-Garrido C; Martínez-Barricarte R; López-Trascasa M; de Córdoba SR; Sánchez-Corral P
    Blood; 2009 Nov; 114(19):4261-71. PubMed ID: 19745068
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome.
    Iatropoulos P; Noris M; Mele C; Piras R; Valoti E; Bresin E; Curreri M; Mondo E; Zito A; Gamba S; Bettoni S; Murer L; Fremeaux-Bacchi V; Vivarelli M; Emma F; Daina E; Remuzzi G
    Mol Immunol; 2016 Mar; 71():131-142. PubMed ID: 26895476
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Autoimmune forms of thrombotic microangiopathy and membranoproliferative glomerulonephritis: Indications for a disease spectrum and common pathogenic principles.
    Skerka C; Licht C; Mengel M; Uzonyi B; Strobel S; Zipfel PF; Józsi M
    Mol Immunol; 2009 Sep; 46(14):2801-7. PubMed ID: 19640589
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Spontaneous hemolytic uremic syndrome triggered by complement factor H lacking surface recognition domains.
    Pickering MC; de Jorge EG; Martinez-Barricarte R; Recalde S; Garcia-Layana A; Rose KL; Moss J; Walport MJ; Cook HT; de Córdoba SR; Botto M
    J Exp Med; 2007 Jun; 204(6):1249-56. PubMed ID: 17517971
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Abbreviated protocol of plasma exchanges for patients with anti-factor H associated hemolytic uremic syndrome.
    Thangaraju S; Khandelwal P; Mishra K; Kumar M; Puraswani M; Saini R; Hari P; Coshic P; Sinha A; Bagga A
    Pediatr Nephrol; 2024 Jul; 39(7):2091-2097. PubMed ID: 38270601
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical and Genetic Characteristics of Atypical Hemolytic Uremic Syndrome in Children: A Chinese Cohort Study.
    Wu D; Chen J; Ling C; Chen Z; Fan J; Sun Q; Meng Q; Liu X
    Nephron; 2021; 145(4):415-427. PubMed ID: 33873197
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.